| Catalog No. | HV212036 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Fusion - [TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BR3, B cell activating factor receptor, CD268)]2 - IGHG1 Fc (Fragment constant) |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q9Y275 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -1201°C. |
|---|
| Alternate Names | BR3-Fc,SS-79,CAS:869881-54-9 |
|---|
| Background | Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA). |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
